Actively Recruiting
Led by Mayo Clinic · Updated on 2025-12-16
40
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for treating patients with pancreatic cancer that has spread to the abdominal area, known as peritoneal metastasis. This phase II trial aims to assess overall survival and disease-free survival in patients with pancreatic adenocarcinoma with limited low volume peritoneal metastasis or positive peritoneal cytology. The study also looks at morbidity outcomes to understand the safety of HIPEC in this group. Participants receive HIPEC treatment combining nab-paclitaxel and cisplatin heated and delivered directly into the abdomen over 90 minutes. Depending on tolerance and disease progression, patients may receive up to five additional HIPEC treatments with paclitaxel and cisplatin. Before treatment, patients undergo imaging scans such as CT, MRI, or PET to assess their condition. During the study, patients are followed every six months after completing treatment to monitor health outcomes. Assessments include imaging scans and clinical evaluations to measure survival and disease progression over up to four years. Safety is monitored by tracking morbidity for 30 days and up to four years. This comprehensive follow-up helps researchers understand the long-term effects of HIPEC for pancreatic cancer with peritoneal spread.
CONDITIONS
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 treatment sessions over an unspecified period
Participants undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with nab-paclitaxel and cisplatin over 90 minutes. Additional HIPEC treatments with paclitaxel and cisplatin may occur up to 5 times depending on disease progression and tolerance.
Up to 5 treatment visits (in-person)
Duration - Up to 4 years
After completing treatment, participants are followed up to monitor overall survival, disease progression, and morbidity outcomes.
Visits every 6 months
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
C
Clinical Trials Referral Office
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hallbera Gudmundsdottir, Jennifer A Yonkus, Cornelius A Thiels...
https://pubmed.ncbi.nlm.nih.gov/37596449